Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The product will be marketed by Dr. Reddy's Laboratories Inc.
Subscribe To Our Newsletter & Stay Updated